‘Very Promising’: Daratumumab as Share of A lot of Myeloma Care

Share II knowledge presented at December’s American Society of Hematology (ASH) virtual meeting showed elevated stringent CR and MDR rates when adding daratumumab (Darzalex) to lenalidomide (Revlimid), bortezomib (Velcade), and dexamethasone (D-RVd) for transplant-eligible myeloma patients.

In this fascinating MedPage At the present time video, Kenneth Shain, MD, PhD, of Moffitt Most cancers Heart in Tampa, Florida, talks about the promising up as a lot as now GRIFFIN trial results, and whether or now not the four-drug combination should always be the fresh similar old of care.

Following is a transcript of his remarks:

Updates this year to ASH, we had been trying at what occurs with the addition of Darzalex to maintenance therapy. So take into fable it as induction transplant consolidation of the upkeep as serious aspects of therapies. That is de facto focusing on what the Darzalex addition to the everyday-of-care maintenance had accomplished. And truly within the stay, what we point to is a serious amplify in a set of the serious stay parts here. All americans is aware of that one, the RVd adopted by D-R maintenance critically improved response rates and depth of response. That formulation sCR rates, which formulation MRD rates, versus RVd similar old and R maintenance, but again with transplant and consolidation in there to boot. We moreover know that the addition of Darzalex to Revlimid maintenance in and of itself improves the depth of response, similar to in sCR rates, to boot to MRD rates after transplant consolidation.

So within the stay, very promising with the addition of Darzalex added to this similar old of care regimen. All americans is aware of that the progression free survival but again is improved, and we’re going to continue to delight in a study how these knowledge former over time and witness how this affects total survival. All americans is aware of that these knowledge are fascinating and truly, to our collectiveness it sounds cherish this D-RVd should always be thought to be a candidate as a capacity fresh similar old-of-be pleased our transplant eligible most average patients. And we know that there is an ongoing, head-to-head segment III watch known as the PERSEUS watch, which is available trying to take care of this question to a elevated degree.

I mediate to place within the context of heaps of experiences that had been accomplished to boot, we know that in transplant ineligible patients, the addition of Darzalex does markedly enhance outcomes when added to similar old-of-care as with D-RD to boot to D-VMP. And clearly, nice segment III knowledge from the CASSIOPEIA knowledge checked out Darzalex plus VTD, and moreover demonstrated improved PFS and met that main endpoint. So but again, within the context of that, this truly does suggest that this quad or four-drug regimen truly should always be thought to be as a capacity fresh similar old of be pleased transplant-eligible a pair of myeloma patients.